Can I prescribe hydroxyzine for anxiety in a patient with a blood urea nitrogen of 25 mg/dL, normal creatinine and normal eGFR, and what dose and frequency are appropriate for severe anxiety?

Hydroxyzine for Severe Anxiety with BUN 25 mg/dL

Yes, you can prescribe hydroxyzine for severe anxiety in this patient with BUN 25 mg/dL and normal creatinine/eGFR; start with 50-100 mg four times daily (QID) as indicated by FDA labeling for anxiety relief. 1

Dosing for Severe Anxiety

The FDA-approved dosing for symptomatic relief of anxiety and tension is:

• Adults: 50-100 mg QID 1
• Adjust dosing based on patient response to therapy 1

For severe anxiety presentations, you should use the higher end of this range (100 mg QID) initially, as the FDA label explicitly states this dosing for anxiety associated with psychoneurosis and organic disease states 1.

Renal Considerations

Your patient's renal function is not a contraindication. A BUN of 25 mg/dL with normal creatinine and eGFR indicates preserved kidney function. While BUN is mildly elevated, this isolated finding without creatinine elevation typically reflects pre-renal factors (dehydration, high protein intake) rather than true renal impairment. Hydroxyzine can be safely prescribed in this scenario.

Evidence Supporting Efficacy

Hydroxyzine demonstrates robust efficacy for generalized anxiety disorder:

• 3-month double-blind trial showed hydroxyzine 50 mg/day significantly reduced Hamilton Anxiety Scale scores compared to placebo (mean change -12.16 vs -9.64, p=0.019), with comparable efficacy to bromazepam but better safety profile except for drowsiness 2

• 4-week multicenter trial demonstrated hydroxyzine superiority over placebo starting from week 1, with sustained benefit through 4 weeks and no rebound anxiety after abrupt discontinuation 3

• The antihistaminic mechanism provides anxiolytic effects without benzodiazepine-related dependence risks 2

Practical Prescribing Algorithm

For severe anxiety:

1. Start 100 mg QID (400 mg total daily dose)
2. Monitor response after 1 week - anxiety reduction should be evident 3
3. Continue for 4 weeks minimum to assess full therapeutic benefit 1
4. Reassess after 4 months, as long-term efficacy beyond this period lacks systematic study 1

Common pitfall: Starting too low. The FDA label specifies 50-100 mg QID for anxiety, not the 25 mg TID dosing used for pruritus 1. Severe anxiety warrants the higher dosing range.

Safety Considerations

• Most common side effect: Transient drowsiness (28% vs 14% placebo), typically appearing in week 1 and resolving with continued use 3
• Other effects: dry mouth (14%), weight gain (12%), loss of concentration (9%) 3
• No withdrawal syndrome or rebound anxiety upon discontinuation, unlike benzodiazepines 3
• Well-tolerated in patients with cardiovascular comorbidities 4

Duration of Treatment

The FDA label notes that effectiveness beyond 4 months has not been systematically assessed 1. Plan to:

• Reassess periodically for continued need
• Consider this a bridge therapy while addressing underlying anxiety through other modalities
• Taper is not required due to absence of withdrawal symptoms 3

Hydroxyzine represents an effective non-benzodiazepine alternative for severe anxiety with a favorable safety profile, appropriate for your patient's clinical scenario.